Translational Oncology (Feb 2019)

miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis

  • Matteo Fassan,
  • Ri Cui,
  • Pierluigi Gasparini,
  • Claudia Mescoli,
  • Vincenza Guzzardo,
  • Caterina Vicentini,
  • Giada Munari,
  • Fotios Loupakis,
  • Sara Lonardi,
  • Chiara Braconi,
  • Marco Scarpa,
  • Edoardo D'Angelo,
  • Salvatore Pucciarelli,
  • Imerio Angriman,
  • Marco Agostini,
  • Renata D'Incá,
  • Fabio Farinati,
  • Roberta Gafà,
  • Giovanni Lanza,
  • Wendy L. Frankel,
  • Carlo Maria Croce,
  • Nicola Valeri,
  • Massimo Rugge

Journal volume & issue
Vol. 12, no. 2
pp. 282 – 291

Abstract

Read online

miR-224 has recently emerged as a driver oncomiR in sporadic colorectal carcinogenesis, but its pathogenetic role is still controversial. A large phenotypical and molecularly characterized series of preinvasive and invasive colorectal lesions was investigated for miR-224 expression by qRT-PCR and in situ hybridization. The caspase-3 and caspase-7 status was also assessed and correlated to miR-224 dysregulation. miR-224 was significantly upregulated during the adenoma-carcinoma sequence and in the context of inflammatory bowel disease dysplastic lesions, whereas its expression was significantly downregulated among BRAF-mutated tumors and in the presence of a DNA mismatch repair deficiency. miR-224 targets caspase-3 and caspase-7 in colorectal cancer, and this inverse relation was already evident from the earliest phases of transformation in intestinal mucosa. The miR-224/caspases axis may represent an interesting field of study for innovative biomarkers/therapeutics for BRAF-mutated/DNA mismatch repair-deficient tumors.